DOCSLIB.ORG

1 EXPORT MARKET FOCUS: INDIA India's Growth Story Remains Strong

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 EXPORT MARKET FOCUS: INDIA India's Growth Story Remains Strong EXPORT MARKET FOCUS: INDIA India's growth story remains strong: Since the early years of liberalization in 1990s, India’s economy has undergone a sea change. It is story of robust economic growth with impressive GDP growth rate. As per United Nations (UN) report, the Indian economy is expected to expand by about 7.5 per cent in 2012-13. The GDP growth was 6.9% during 2011-2012 while during the earlier 2 preceding years it was 8.4%. “India's growth story remains strong,” says the Finance Minister of India, Mr. P. Chidambaram. He was speaking at Annual conference of Economic Editors in New Delhi recently. Even though Indian economy’s growth declined to 6.5 per cent in 2011-12 and further to 5.5 per cent in the first quarter of this fiscal, it is no cause for undue worry,” he said silencing critics. The government has already taken a slew of reform measures including allowing FDI in multibrand retail and allowing foreign carriers pick up stake upto 49 per cent in Indian aviation companies. The government has also reduced subsidies on petroleum products by increasing diesel prices and putting cap on the number of subsidized LPG per family to six a year. A few months ago, the government also opened up insurance and pension sectors to foreign investment. Foreign investment in pension sector is to be raised to 49%. In the insurance sector, FDI will be raised to 49 % from the current 26%. Also, reforms are underway in energy sector which includes restructuring of State Electricity boards. Other important areas of reforms are education and labor laws. India was one of the few economies in the world that sailed through the global economic crisis, thanks to the strong fundamentals of Indian economy. According to the Global Competitiveness report 2010-11, India ranks 51st among 139 countries. India ranks higher than many countries in key parameters such as market size (4th) and innovation (39th). It also has a sound financial market (17th). 1 According to UNCTAD's World Investment Prospects Survey 2010-2012, India is the second-most attractive destination for FDI in the world. Indian markets have significant potential and offer prospects of high profitability and a favorable regulatory regime for investors. Interesting facts about India’s economy: Here are some interesting facts about India’s growing economy are: Three Indian bourses - NSE, MCX and BSE - have made it to the world's top 20 derivative exchanges. The eight core sectors—coal, crude oil, natural gas, petroleum refinery products, steel, cement and electricity—touched a seven-month high, growing by 5.1 per cent in September 2012. India's tablet personal computer (PC) market is expected to touch 7.3 million units by 2015-16, from around 1.7 million units currently. Five Indian companies—Larsen & Toubro, Hindustan Unilever, Infosys, TCS and Sun Pharma—have entered the list of world's 50 most innovative firms. India has emerged as one of the top five investment destinations in the world. Drivers of Growth: India’s growth is driven by domestic consumption. Increasing standard of living, growing middle class with greater purchasing power and young demography are some of the key factors that are creating demand across sectors. India is a young nation. More than 50% of India's current population is below the age of 25 and over 65% below the age of 35. Thus India has the biggest young and working population in the world. And this young upwardly mobile population is expected to drive the demand for high end consumer products. 2 What is interesting is that rural India where around 70% of India’s population resides is increasingly linked with the mainstream economy. As put it by Hindustan Unilever Ltd (HUL) Chairman Harish Manwani while speaking at their Annual General Meeting, “Rural India is now becoming the epicentre of India's growth story”. According to a research report published by CRISIL Research in September 2012, for the first time in last 25 years, rural spending outpaced urban consumption during 2009-10 and 2011-12. Rural consumption per person grew annually at 19 per cent which is 2 percentage points higher than its urban counterpart. Some of the potential sectors for exports for Pennsylvania companies: India’s growth phenomenon is witnessed across all industry sectors and opportunities exist tremendously. We have mentioned below opportunities and developments only in a few sectors. Infrastructure: India is projected to spend some US $1 trillion by 2020 on a spectrum of infrastructure projects - roads, ports, airports, power (including nuclear) and urban regeneration/rail, new cities and towns. Infrastructure project completion is expected to go up by 39 per cent during FY 2012- 13. The infrastructure sector accounts for 26.7 per cent of India's industrial output. The Index of Eight core industries—crude oil, petroleum refinery products, coal, electricity, cement, steel, fertilizers and natural gas—having a combined weight of 37.90 per cent in the Index of Industrial Production (IIP) stood at 147.3 in July 2012, according to data released by the Union Ministry of Commerce and Industry. According to Goldman Sachs, India's infrastructure sector will require US$ 1.7 trillion investment in the next 10-years. Further, India needs to spend US$ 1.2 trillion by 2030 to meet the projected demand of its cities, according to a McKinsey Global Institute Report. 3 Airport modernization, Highways, upgrading rail infrastructure (new rail lines and high speed rail) and development of ports are some of the focused areas whenever private sector investment is significant. Advanced Engineering and Manufacturing: India is a leading automotive manufacturer, with significant effort being placed on green technology. India's manufacturing sector is also developing fast, with world- class companies such as Bharat Forge, Tata Motors, and Mahindra. India needs an investment of US$ 200 to 300 billion military and aerospace sectors in 2 decades. India’s Defense sector envisages steep growth driven by modernization plans and increased focused on homeland security The rapid growth of this industry has attracted major global aerospace companies to India. Mining: Estimates indicate that investment opportunities valued at US$30 to $40 billion will be available over next 8 to 10 years to develop new mines and manufacture and sale state of art mining equipment and technology Environmental Technologies: Rapid industrialization and urbanization has had adverse impact on the environment in India. This in fact makes, India as one of the fastest growing market for Environmental technologies. Opportunities include in the following sub-sectors: Environmental monitoring & measuring, clean technologies and solutions for industrial pollution control, environmental analysis & consultancy, waste management and recycling, and Renewable energy technologies. Food and Food processing: Although India is the 3rd largest producer of food after China and the US, it is interesting to note that India is also a major importer of many agricultural 4 commodities. Imported processed food items like, pasta, cake mixes, dried fruits and nuts, processed fruits and vegetables, chocolate syrups, fruit juices, ketchup, chocolates, sauces, specialty cheeses, potato chips, and cookies are increasingly popular among the consumers in metropolitan cities. The number of Indians eating out and interested in trying intentional cuisine have also increased, this has given a boost to emergence of new hotels and specialty restaurants. Also, post liberalized India is witnessing growth of international fast food chains (Mc Donald’s, KFC etc). Pennsylvania exporters have opportunities to supply food products to these chains. At present just 6 % of the food items are being processed in India in contrast to the developed nations where about 60% to 80% of the food produced is processed. The other sectors that are witnessing phenomenal growth are organized food retailing and food services which are growing at annual rate of about 25%. Healthcare: medical equipment The Indian healthcare industry is witnessing rapid growth and undergoing a transformation due to increasing private sector participation. Currently estimated at $ 35 billion, the healthcare sector holds immense opportunities for Pennsylvania companies to grow their export market. Growing middle class in India is expecting medical services of International standards. Also, medical tourism is booming in India. As a result a lot of new super specialty hospitals are coming up leading to demand for hi-tech medical equipment. Indian pharma and biotech companies are increasingly becoming influential internationally and going global. Education: PA India Office closely works with Pennsylvania based Universities in their efforts to reach out to Indian students for recruitment. India continues to be the second largest source of international students in the US. The number of Indian students enrolled in US institutions of higher education in 2010/11 continues to be over hundred 5 thousand at 103,895. India still represents 14% of all international students in US higher education, making it the number two country. Accessing Opportunities in Indian market: Pennsylvania companies have tremendous opportunities in Indian market. In fact Pennsylvania’s exports to India have been growing significantly over the past few years. Pennsylvania companies have access to the services provided by Pennsylvania’s Authorized Trade Representative based in Bangalore. The services include: Market research and Entry strategy, Agent/Distributor/ Representative search, Information on Certification/Standards and Regulatory requirements, Trade leads and follow up with existing clients / agent Foreign company background checks Information on custom duties and various business taxes in India, In-country-assistance during visit to India, Assistance in participation in trade shows Organizing / assisting with trade missions to India CTD Trade Mission to India in February 2013: Visiting the market to meet with potential business partners face-to-face & taking firsthand experience of the market is very crucial while exploring export opportunities in Indian market.
Load more

Recommended publications
  • A STUDY on BEHAVIOUR PATTERN of DIVIDEND PAY-OUT: SELECTED BLUE-CHIP COMPANIES in INDIA Author Co - Author Dr.K.R.Sivabagyam A.Ranjitha Assistant Professor K
    Compliance Engineering Journal ISSN NO: 0898-3577 A STUDY ON BEHAVIOUR PATTERN OF DIVIDEND PAY-OUT: SELECTED BLUE-CHIP COMPANIES IN INDIA Author Co - Author Dr.K.R.Sivabagyam A.Ranjitha Assistant Professor K. Madhu Varshini Department of Commerce N.Deekshithaa Sri Krishna Arts and Science College S. Kabilambika E-mail Id: [email protected] II M.Com Students MOB: 7871809789 E-mail Id: [email protected] [email protected] [email protected] [email protected] Mob: 9486939255; 9715184177; 9025868186 ABSTRACT Reliance Industries, Tata Consultancy services (TCS) and WIPRO in India and The term blue-chip was used to describe observe the behaviour pattern of the three high- priced stocks in 1923 when Oliver measures of dividend policy of the blue- Gingold, an employee at Dow Jones chip companies in India. observed certain stocks trading at $200 or more per share. Poker players bet in blue, KEYWORDS: Blue Chip Companies, white and red chips with blue chips having Dividend Policy, Investment Proposals. more value than both red and white chips. INTRODUCTION Today, blue chips stocks don’t necessarily refer to stocks with a high price tag, but In the exchange of India there are literally more accurately to stocks of high-quality thousands of companies but when it comes companies that have with stood the test of to financial stability only few companies time. A blue-chip company is a are financially stable and in other financial multinational firm that has been in aspects. Long term investors seek out for operation for a number of years.
    [Show full text]
  • SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP
    Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M.
    [Show full text]
  • Consumer Goods on Path to Recovery; Essentials Hold an Upper Edge Sector Update
    Consumer Goods On path to recovery; Essentials hold an upper edge Sector Update Most consumer goods companies started Q4FY2020 with good growth, as Q4FY2020 Results Review gradual recovery was seen in the demand environment (especially in rural markets). However, the outbreak of COVID-19 resulted in a complete lockdown Sector: Consumer Goods in India in the last 10-15 days of March, leading to complete stoppage of production and disruption in supply chain. This impacted sales volumes of most Sector View: Positive companies at the fag end of the quarter, resulting in weak Q4FY2020 numbers. Volumes of most companies (barring food companies) under our coverage declined by 3-22% in Q4FY2020 (revenue of Sharekhan universe declined by 7.8% y-o-y). Companies such as Britannia Industries and Tata Consumer Products Our coverage universe (TCPL) registered growth of 2.5% and 5-6% (at organic level), respectively, in Q4FY2020. On the other hand, companies such as Godrej Consumer Products CMP PT Companies Reco. (Rs) (Rs) (GCPL), Emami, Jyothy Labs, and Dabur India posted double-digit decline in revenue, as pre-season inventory loading by dealers/distributors was affected Asian Paints 1,709 Buy 1,987 by the lockdown. On the international front, companies having large presence Britannia in Africa, Middle East and South East Asian countries registered lower sales in 3,623 Buy 4,060 Industries the international business affected by lockdown and macro headwinds. Lower raw-material prices (especially crude-linked inputs) and lower packaging costs Colgate- 1,383 Positive 1,551 aided gross margins of some companies to expand by 100-300 bps.
    [Show full text]
  • Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times
    12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis.
    [Show full text]
  • Pharmaceuticals Stellar Quarter; Healthy Outlook Sector Update
    Pharmaceuticals Stellar quarter; Healthy Outlook Sector Update Q2FY2021 was yet another stellar quarter for pharmaceutical companies under Q2FY2021 Results Review Sharekhan’s pharma universe. The quarter witnessed a sustained improvement in Sector: Pharmaceuticals the US business while the domestic business showed signs of improvement. The overall plant utilization levels during Q2FY2021 were at normal levels (as against Sector View: Positive relatively low utilization levels in previous quarter), thus yielding costs benefits. For the quarter, the pharma companies delivered revenue growth of 8.8% y-o-y, while sequentially as well it clocked a growth of 8.3%. Topline performance was better than estimates and was driven by sturdy performance of the US business, while the India operations also grew a decent pace. Growth in the base business, stabilizing price erosion and new launches led to the growth in US business, while in India business, companies with a relatively higher share of chronic business grew strongly and outperformed the industry. Select players such as Aurobindo, Cadila and Cipla reported strong 12.5%, 18% and 10% y-o-y growth respectively in the US business. Divis labs also reported a strong 21% y-o-y growth in the topline backed by a strong performance in the API segment, while Laurus labs posted a 60% revenue Our active coverage universe growth on the back of an impressive growth in the formulations segment. Operating CMP PT profit for the universe increased sharply by 21% y-o-y. Operating margin also Companies Reco. (Rs) (Rs) expanded by 251 bps y-o-y, better the expected 150 bps y-o-y expansion.
    [Show full text]
  • Saturday, 23Rd August 2014 Index Levels : Market Trend (Nifty)
    ` Saturday, 23rd August 2014 Index Levels : Market Trend (Nifty): Trend Reversal Point INDEX SUPPORTS RESISTANCES Period Current Trend (TRP)Nifty close basis NIFTY# 7930/8000/8090 Short Term Trend UP DOWN BELOW 7750 (7913.20) 7850/7760 SENSEX# 26250/26000 26550/26700/27200 Medium Term UP DOWN BELOW 7650 (26419.55) ITE-35* -------- -------- Long Term Trend UP DOWN BELOW 6500 (10239.68) ND #as on 22 August 2014 Imtiaz Merchant’s Best Picks: Indices: CURRENT Domestic COMPANY NAME SIZE SECTOR Close Points % Chg PRICE Indices Large Cipla Health Care 499 BSE Sensex 26419.55 59.44 0.23 % Cap Large Industrials and UPL 338 Nifty 7913.20 22.10 0.28 % Cap Capital Goods ITE Shariah 10239.68 42.83 0.42 % 35* S&P CNX 500 1919.15 4.92 0.12 % Note: (Buying should be done from a medium to long term perspective) Shariah Advance/ Advance Decline AD Un- Market Brief Decline Ratio Changed BSE 1462 1572 0.93:1 114 On the back of positive global cues and some NSE 693 782 0.89:1 60 reform announcements by the Union Shariah Government, the markets on Friday ended the Universe*** 291 269 1.08:1 15 day and the week on positive note; Auto, Info. Technology and Health Care sectors were the flavor of the week. The undertone appears to Global Indices Close Points % Chg be bullish. All the trends are up. More reform Dow Jones* 16979.13 60.36 0.36% announcements from the Govt. and good NASDAQ* 4526.48 5.62 0.12% corporate results will further fuel the rally and FTSE* 6755.48 22.18 0.33% the Nifty is likely to see the 8000 level soon.
    [Show full text]
  • Loan Against Securities – Approved Single Scrips
    Loan against securities – Approved Single Scrips SR no ISIN Scrip Name Margin 1 INE216A01030 BRITANNIA INDUSTRIES LIMITED 50 2 INE854D01024 UNITED SPIRITS LIMITED 50 3 INE437A01024 APOLLO HOSPITALS ENTERPRISE LTD 50 4 INE208A01029 ASHOK LEYLAND LTD 50 5 INE021A01026 ASIAN PAINTS LTD 50 6 INE406A01037 AUROBINDO PHARMA LTD 50 7 INE917I01010 BAJAJ AUTO LTD 50 8 INE028A01039 BANK OF BARODA 50 9 INE084A01016 BANK OF INDIA 50 10 INE463A01038 BERGER PAINTS INDIA LTD 50 11 INE029A01011 BHARAT PETROLEUM CORPORATION LTD 50 12 INE323A01026 BOSCH LTD 50 13 INE010B01027 CADILA HEALTHCARE LTD 50 14 INE059A01026 CIPLA LTD 50 15 INE522F01014 COAL INDIA LTD 50 16 INE259A01022 COLGATE-PALMOLIVE (INDIA) LTD 50 17 INE361B01024 DIVIS LABORATORIES LTD 50 18 INE089A01023 DRREDDYS LABORATORIES LTD 50 19 INE129A01019 GAIL (INDIA) LTD 50 20 INE860A01027 HCL TECHNOLOGIES LTD 50 21 INE158A01026 HERO MOTOCORP LTD 50 22 INE038A01020 HINDALCO INDUSTRIES LTD 50 23 INE094A01015 HINDUSTAN PETROLEUM CORPORATION LTD 50 24 INE030A01027 HINDUSTAN UNILEVER LTD 50 25 INE079A01024 AMBUJA CEMENTS LTD 50 26 INE001A01036 HOUSING DEVELOPMENT FINANCE CORPLTD 50 27 INE090A01021 ICICI BANK LTD 50 28 INE242A01010 INDIAN OIL CORPORATION LTD 50 29 INE009A01021 INFOSYS LTD 50 30 INE154A01025 ITC LTD 50 31 INE237A01028 KOTAK MAHINDRA BANK LTD 50 32 INE498L01015 LT FINANCE HOLDINGS LTD 50 33 INE018A01030 LARSEN TOUBRO LTD 50 34 INE326A01037 LUPIN LTD 50 35 INE101A01026 MAHINDRA MAHINDRA LTD 50 36 INE585B01010 MARUTI SUZUKI INDIA LTD 50 37 INE775A01035 MOTHERSON SUMI SYSTEMS LTD 50 38 INE883A01011
    [Show full text]
  • In the United States District Court for the Eastern District of Michigan
    Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 1 of 11 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN ABBOTT LABORATORIES and ) ABBOTT RESPIRATORY LLC, ) ) Plaintiffs, ) ) C.A. No. 2:10-cv-10656 v. ) ) SUN PHARMACEUTICAL INDUSTRIES, LTD. ) and SUN PHARMA GLOBAL FZE, ) ) Defendants. ) COMPLAINT Plaintiffs Abbott Laboratories and Abbott Respiratory LLC (collectively, “Abbott”), by their attorneys, hereby allege as follows: Nature of the Action This is an action for patent infringement of U.S. Patent Nos. 6,080,428 (“the ‘428 patent”) and 6,469,035 (“the ‘035 patent”), arising under the patent laws of the United States, Title 35, United States Code, 35 U.S.C. §§ 271 and 281. This action relates to Abbreviated New Drug Application (“ANDA”) No. 20-0484 filed by Sun Pharma Global FZE (“Sun FZE”) with the U.S. Food and Drug Administration (“FDA”) for approval to market 500 mg and 1000 mg niacin extended-release tablets that are generic versions of the 500 mg and 1000 mg strength versions of Abbott’s highly successful NIASPAN® drug product. Related Actions The present action is related to an identical patent infringement action pending before the United States District Court for the District of Delaware, Abbott Laboratories and Abbott Case 2:10-cv-10656-AC-MKM Document 1 Filed 02/16/10 Page 2 of 11 Respiratory, LLC v. Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceuticals, Inc. (C.A. 10-cv-112) (the “Delaware Sun Action”), pertaining to ANDA No. 20-0484 filed by Sun FZE for approval to market generic versions of Abbott’s 500 mg and 1000 mg strength NIASPAN® tablets.
    [Show full text]
  • INDIA OUTBOUND T&A Consulting Volume 6 Issue 4 3Rd April, 2017
    INDIA OUTBOUND T&A Consulting Volume 6 Issue 4 3rd April, 2017 As the Financial Year comes to an end so has an eventful The trend among Indian pharma firms of “building brands“ quarter. With the liquidity shock of de-monetization having been continued, with Aurobindo Pharma adding to its portfolio of managed and a healthy, albeit counter-intuitive GDP data biosimilars acquired from a Swiss firm and leveraging market (annualised GDP growth at 7.0% for Oct-Dec Qtr) having access across specialized therapeutic segments provided by a established the soundness of macroeconomic fundamentals, the Portugese generics firm. Also active was Piramal Enterprises, high for the current Government came in the form of results for acquiring the drug portfolio of UK-based Mallinckrodt LLC to reach a the Uttar Pradesh elections. The win for the Bhartiya Janata targeted segment across eight European markets. Sun Pharma and Party in U.P. has consolidated its hold at the Centre and across Zydus Cadilla were active in North America, with Zydus acquiring a India. What that means going forward is further stability on US drug firms for a sizeable cheque to bolster its specialty India’s policy front. Case in point has been the Government’s pharmaceuticals segment whilst Sun Pharma acquired a small push in the on-going budget session of Parliament to meet the Canadian drug discovery firm. On the IT front, the bigger boys of Indian July 2017 deadline in implementing the Goods and Services IT were active acquiring assets in Latin America and their preferred market Tax. The outbound investment story nevertheless continues - United States.
    [Show full text]
  • Chairperson Speech 2021-Final.Cdr
    Unwavering Purpose Chairperson’s AGM Speech 43rd Annual General Meeting Friday, July 23, 2021, Bengaluru, India Kiran Mazumdar-Shaw Executive Chairperson 2 Dear Shareholders, As we connued with our operaons, we also focused on protecng our people and ensuring It gives me great pleasure to welcome you their health and well-being. We invested in to the 43rd Annual General Meeting of implemenng strict safety protocols and your company. regularly engaged with our people to keep them movated. The leadership team constantly The pharmaceutical and healthcare monitored the fast-evolving situaon and took industry's fight against COVID-19 data-driven decisions for operaonal planning across our facilies. intensified over the past year as fresh waves of infections hit many countries REALIZING THE BIOSIMILARS PROMISE around the world. As the pandemic left societies and economies in disarray, Our Biosimilars business revenue at Rs 28,002 million, recorded a growth of 21% in FY21. We biotechnology-led companies quickly commercialized our third biosimilar, Insulin developed diagnostics, vaccines and Glargine, in the U.S. and obtained regulatory therapies to tilt the battle in favor of approvals for key biosimilars Bevacizumab and humanity. Insulin Aspart in the European Union. Our biosimilars benefited 3.1 million paents during India has been at the forefront of this the year. crusade, producing cost-effective As the only company from India to have three vaccines at scale for millions of people. biosimilars commercialized in the U.S. and among At the same time, the country has the select few globally to have five biosimilars approved in Europe, we are confident of enabling continued to supply the world with affordable access to expensive biologic drugs for generic and biosimilar therapies to millions of paents globally.
    [Show full text]
  • Annual-Report-1.Pdf
    p Composite Default screen Cover.prn D:\SUN BACK UP\Sun annula report-03-04\H8532 COVER and BK Aws.cdr Monday, August 22, 2005 12:23:20 PM p Composite Default screen Inside Ft.prn D:\SUN BACK UP\Sun annula report-03-04\H8532 COVER and BK Aws.cdr Monday, August 22, 2005 12:25:28 PM Color profile: Disabled Composite 175 lpi at 45 degrees A female bias for the blues? For long, scientists have observed that women are more vulnerable to depression. For long, this has been attributed by turns to an excitable nervous system, the opposing tugs of work and family. Researchers are now looking for a scientific reason for this discrepancy and it may be because of genes. Scientists say that depression in women is a global phenomenon cutting across class divides, spanning life experiences. Several genes, along with the surges in hormones may influence brain chemistry and trigger The cover shows 2 images from breakthroughs in depression. A risk factor linked to ruminating, over thinking, mulling over issues and re- neuroscience: a neuron, an MRI scan. living sad incidents is more common in women and could lead on to depression. However, half the risk could be genetic, with areas that cause this deep sadness now Two ideas that took learning from one field,and in an identified. And these genes act in concert with estrogen receptors with variations in sex inspired moment, “a flash of lightening” showed hormones in a complex interplay of hormones, neurotransmitters and receptor how best they could be applied to another field, activation.
    [Show full text]
  • Hindustan Unilever Limited
    Hindustan Unilever Limited Shift to Biomass Fired Burners CASE STUDY Figure 1: Nashik Biomass Boiler Figure 2: Orai Burner for incorporation of Vegetable Oil Residue Summary Hindustan Unilever Limited (HUL) has more than 20 manufacturing sites, where fossil fuel is being used to generate steam and hot air for process heating. To minimize our dependence on conventional fossil fuels and reduce CO2 emissions, the company started focusing on renewable energy opportunities since 2009. Prior to this, only 5 of our sites had biogenic fuel firing. A long-term road map for conversion of major fuel consuming sites was drawn-up. Since then, the company has commissioned 10 biomass fired Boilers and Hot Air Generators in India. Presently, more than 60,000 T of biogenic fuel is utilized annually for our process heating. Objective of Intervention The objective of the case study is to demonstrate the impact of biomass-based fuel usage on CO2 reduction along deliverance of cost savings. Type of Intervention and Location The intervention is to increase the share of renewable energy in HUL’s overall energy consumption portfolio by maximizing utilization of biomass fired fuels and reducing dependence on fossil fuels. The Reinforcing India’s Commitment Page 1 sites of intervention are the following locations where biomass-fired burners have been installed post-2010. These include biomass fuel-based Hot Air Generators (HAG) and Boilers (BMB): Chiplun (HAG), Goa (BMB), Haldia (HAG), Haridwar (BMB), Hosur (BMB), Mysore (BMB), Nashik (BMB), Orai (BMB), and Rajpura (HAG and BMB). Description of Intervention Since 2009, we have invested more than INR 60 crores in installation of Biomass Fired Steam Boilers and Hot Air Generators.
    [Show full text]